JP2002506445A - スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法 - Google Patents

スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法

Info

Publication number
JP2002506445A
JP2002506445A JP50459399A JP50459399A JP2002506445A JP 2002506445 A JP2002506445 A JP 2002506445A JP 50459399 A JP50459399 A JP 50459399A JP 50459399 A JP50459399 A JP 50459399A JP 2002506445 A JP2002506445 A JP 2002506445A
Authority
JP
Japan
Prior art keywords
independently
attached
catalyst
nitrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50459399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506445A5 (enExample
Inventor
サルベミニ，ダニエラ
Original Assignee
ジー．ディー．サール アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー．ディー．サール アンド カンパニー filed Critical ジー．ディー．サール アンド カンパニー
Publication of JP2002506445A publication Critical patent/JP2002506445A/ja
Publication of JP2002506445A5 publication Critical patent/JP2002506445A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
JP50459399A 1997-06-20 1998-06-15 スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法 Ceased JP2002506445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
US60/050,402 1997-06-20
PCT/US1998/012231 WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Publications (2)

Publication Number Publication Date
JP2002506445A true JP2002506445A (ja) 2002-02-26
JP2002506445A5 JP2002506445A5 (enExample) 2007-12-06

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50459399A Ceased JP2002506445A (ja) 1997-06-20 1998-06-15 スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法

Country Status (12)

Country Link
US (2) US6180620B1 (enExample)
EP (1) EP1001752B1 (enExample)
JP (1) JP2002506445A (enExample)
AT (1) ATE256467T1 (enExample)
AU (1) AU733415B2 (enExample)
CA (1) CA2294155A1 (enExample)
DE (1) DE69820633T2 (enExample)
DK (1) DK1001752T3 (enExample)
ES (1) ES2215305T3 (enExample)
PT (1) PT1001752E (enExample)
WO (1) WO1998058636A1 (enExample)
ZA (1) ZA985376B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513948A (ja) * 2003-12-11 2007-05-31 アルコン，インコーポレイテッド 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物
JP2014526562A (ja) * 2011-09-26 2014-10-06 ガレラ・セラピューティクス・リミテッド・ライアビリティ・カンパニー 疾患の治療方法
JP2018525388A (ja) * 2015-08-11 2018-09-06 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
US10610533B2 (en) 2006-10-12 2020-04-07 Galera Labs, Llc Methods of treating oral mucositis
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US12156863B2 (en) 2016-09-01 2024-12-03 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
DE69813898T2 (de) 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
ATE312103T1 (de) * 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
ES2240101T3 (es) 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
DE60235955D1 (de) * 2001-01-05 2010-05-27 Metaphore Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
DK1392328T3 (da) 2001-01-19 2009-11-09 Nat Jewish Health Medikament til beskyttelse i radioterapi
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
JP4369124B2 (ja) * 2001-03-02 2009-11-18 メタファー・ファーマシューティカルズ・インコーポレイテッド 金属錯体のクロマトグラフィー
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
US20040236519A1 (en) * 2001-06-08 2004-11-25 Marshall Garland R. Libraries of confomationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
CA2451602A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
DE60231246D1 (de) * 2001-12-14 2009-04-02 Alcon Inc Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2003103680A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
MXPA05005240A (es) * 2002-12-06 2005-07-25 Alcon Inc Imitadores de la superoxido - dismutasa para el tratamiento de desordenes y enfermedades oculares.
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
DK2300003T3 (da) 2008-05-23 2014-05-26 Nat Jewish Health Forbindelser til anvendelse i behandling af skade forbundet med eksponering for en alkylerende art
JP2020507598A (ja) 2017-02-15 2020-03-12 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 局所腸送達のためのペンタアザマクロ環錯体
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3167087A1 (en) * 2020-02-13 2021-08-19 Anantha Rajmohan MUTHUSAMY Solid state forms of avasopasem manganese and process for preparation thereof
WO2025024390A2 (en) * 2023-07-21 2025-01-30 Galera Labs, Llc Carcinogenesis reduction with pentaaza macrocyclic ring complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1997033877A1 (en) 1996-03-13 1997-09-18 Monsanto Company Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513948A (ja) * 2003-12-11 2007-05-31 アルコン，インコーポレイテッド 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物
US10610533B2 (en) 2006-10-12 2020-04-07 Galera Labs, Llc Methods of treating oral mucositis
US11612608B2 (en) 2006-10-12 2023-03-28 Galera Labs, Llc Methods of treating oral mucositis
JP2023027289A (ja) * 2011-09-26 2023-03-01 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 疾患の治療方法
JP2014526562A (ja) * 2011-09-26 2014-10-06 ガレラ・セラピューティクス・リミテッド・ライアビリティ・カンパニー 疾患の治療方法
JP2018035162A (ja) * 2011-09-26 2018-03-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
JP7697688B2 (ja) 2011-09-26 2025-06-24 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 疾患の治療方法
US10493081B2 (en) 2011-09-26 2019-12-03 Galera Labs, Llc Methods for treatment of diseases
JP2020183416A (ja) * 2011-09-26 2020-11-12 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
US11826373B2 (en) 2011-09-26 2023-11-28 Galera Labs, Llc Methods for treatment of diseases
US12077549B2 (en) 2015-08-11 2024-09-03 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
JP7041959B2 (ja) 2015-08-11 2022-03-25 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
JP2022023183A (ja) * 2015-08-11 2022-02-07 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
US11066433B2 (en) 2015-08-11 2021-07-20 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
US10597415B2 (en) 2015-08-11 2020-03-24 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
JP2018525388A (ja) * 2015-08-11 2018-09-06 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
US12156863B2 (en) 2016-09-01 2024-12-03 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US12551581B2 (en) 2017-04-13 2026-02-17 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Also Published As

Publication number Publication date
PT1001752E (pt) 2004-05-31
AU733415B2 (en) 2001-05-17
US6180620B1 (en) 2001-01-30
EP1001752B1 (en) 2003-12-17
DE69820633D1 (de) 2004-01-29
DE69820633T2 (de) 2004-09-23
WO1998058636A1 (en) 1998-12-30
ES2215305T3 (es) 2004-10-01
EP1001752A1 (en) 2000-05-24
DK1001752T3 (da) 2004-04-19
AU8068598A (en) 1999-01-04
US6395725B1 (en) 2002-05-28
CA2294155A1 (en) 1998-12-30
ATE256467T1 (de) 2004-01-15
ZA985376B (en) 1999-06-21

Similar Documents

Publication Publication Date Title
US6395725B1 (en) Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
JPS6075429A (ja) 鎮痛用組成物
JPS6084251A (ja) 鎮痛用新規化合物および組成物
JPH0510334B2 (enExample)
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
HUE026994T2 (en) Liquid nasal spray containing low dose naltrexone
EP0278821A1 (fr) Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis
PT1096936E (pt) Tratamento da discinesia
AU2021204517B2 (en) Combination of opioids and n-acylethanolamines
US20040147498A1 (en) Combinations of superoxide dismutase mimetics and nonsteroidal analgesic / anti-inflammatory drugs
CA3053779A1 (en) Pentaaza macrocyclic ring complexes for local intestinal delivery
JP2001513506A (ja) タイプｉｉ糖尿病のクロム／ビオチン治療
JP2000506170A (ja) 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物
US20050171198A1 (en) SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
FR2556216A1 (fr) Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques
WO2005041886A2 (en) Methods for generating or increasing revenues related to pain inhibitor commerce
RU2823100C2 (ru) Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения
WO2019151409A1 (ja) 鎮痛剤及び鎮静剤
Vadivelu et al. Buprenorphine pharmacology and clinical applications
JPH0326171B2 (enExample)
Klebe Classical Drug Research
WO2025198489A1 (ru) Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения
WO2005060437A2 (en) Composition combinations and methods for treating, preventing, reversing and inhibiting pain
JP2023094736A (ja) 疼痛治療薬
TW202132291A (zh) 使用苯氧丙胺化合物治療疼痛的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090512

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20090929